Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Cotitwoon Sep 11, 2017 10:23pm

126 Views

Post# 26682941

Gamechanger

I was told Coti has a number of NDA's signed with Big Pharma. They check in on a regular basis asking about the human trials.Good results will get there attention

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market